Verition Fund Management
RAPT

Verition Fund Management’s RAPT Therapeutics RAPT Stock Holding History

Verition Fund Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,978
Closed -$170K – 3465
2024
Q2 		$170K Buy
+6,978
New +$322K ﹤0.01% 2643

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Verition Fund Management's RAPT Position: Q3 2024 in Review

Verition Fund Management sold out of RAPT Therapeutics (RAPT) in Q3 2024, closing a stake of 6,978 shares — an estimated $170K sold.

Verition Fund Management first reported a position in RAPT in Q2 2024 and held it in 1 quarter. The position peaked at $170K in Q2 2024. 94 funds tracked by Wall St. Rank hold RAPT as of Q3 2024.

  • Verition Fund Management reported no remaining RAPT Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Verition Fund Management sold 6,978 RAPT Therapeutics shares in Q3 2024, an estimated $170K.
  • Verition Fund Management first reported a position in RAPT Therapeutics in Q2 2024 and held it in 1 quarter.
  • Verition Fund Management's RAPT Therapeutics position peaked at $170K in Q2 2024.
  • 94 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.